Expanded role for ARBs in cardiovascular and renal disease? Recent observations have far-reaching implications

Postgraduate Medicine

Volumn 109, Issue 4, 2001, Pages 115-122

  Ramahi, T M ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; AMLODIPINE; ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN I; ANGIOTENSIN II [3-8]; ANGIOTENSIN RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ANGIOTENSINOGEN; ATENOLOL; BRADYKININ; CANDESARTAN HEXETIL; CAPTOPRIL; CATHEPSIN G; CHYMASE; CV 1974; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DRUG METABOLITE; EPROSARTAN; HYDROCHLOROTHIAZIDE; IRBESARTAN; LOSARTAN POTASSIUM; PLACEBO; RENIN; TELMISARTAN; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG; VALSARTAN;

ARTICLE; CARDIOVASCULAR AUTOREGULATION; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; DIABETIC NEPHROPATHY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDICATION; HEART FAILURE; HORMONAL REGULATION; HUMAN; HYPERTENSION; PATHOPHYSIOLOGY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SIGNAL TRANSDUCTION;

EID: 0035051986     PISSN: 00325481     EISSN: None     Source Type: Journal    
DOI: 10.3810/pgm.2001.04.911     Document Type: Article

References (23)

1. Angiotensin II receptor antagonists
2. 1-receptor blockers in hypertension and heart failure: Clinical experience and future directions
3. Angiotensin receptors and their antagonists
4. Tissue angiotensin system in cardiovascular medicine: A paradigm shift?
5. The reninangiotensin system in the vessel wall
6. Cell biology and genetics of angiotensin in cardiovascular disease
7. 2-receptor mediates inhibition of cell proliferation in coronary endothelial cells
8. Heterogeneity of angiotensin synthetic pathways and receptor subtypes: Physiological and pharmacological implications
9. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators
10. Angiotensin II receptor blockers: Review of the binding characteristics
11. Vasculoprotective and cardioprotective mechanisms ofangiotensin-converting enzyme inhibition: The homeostatic balance between angiotensin II and nitric oxide
12. Losartan potassium: A review of its pharmacology, clinical efficacy and tolerability in the management of hypertension
13. Pharmacology of valsartan, an angiotensin II receptor antagonist
14. Irbesartan: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in the management of hypertension
15. Candesartan cilexetil: A new, long-acting, effective angiotensin II type 1 receptor blocker
16. Telmisartan
17. Eprosartan
18. Angiotensin 11 antagonists for hypertension: Are there differences in efficacy?
19. Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension
20. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: Randomised trial - The Losartan Heart Failure Survival Study ELITE II
21. The effect of angiotensin-convertingenzyme inhibition on diabetic nephropathy. The Collaborative Study Group
22. Effects of the angiotensin II antagonist valsartan on blood pressure, proteinuria, and renal hemodynamics in patients with chronic renal failure and hypertension
23. Combination ACE inhibitor and angiotensin II receptor antagonist therapy in diabetic nephropathy